Products with Antiangiogenic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1226 | 10-Hydroxycamptothecin |
| 10-Hydroxycamptothecin is a cell-permeable powerful DNA topoisomerase I inhibitor. It has selective inhibitory effect on the phosphorylation of histone H1 and H3, but less effect on other histones.10-Hydroxycamptothecin anticancer, and antiangiogenic activities, it can prevent fibroblast proliferation and epidural scar adhesion after laminectomy in rats. | |
| BCN1281 | Norcantharidin |
| Norcantharidin has been used to treat human cancers in China since 1984, it inhibits the canonical Wnt signal pathway in NSCLC, by activating WIF-1 via promoter demethylation; it also enhances TIMP‑2 antitumor and anti‑vasculogenic mimicry activities in GBCs through downregulating MMP‑2 and MT1‑MMP. Norcantharidin is a protein phosphatase type-2A inhibitor, which has less nephrotoxic and phlogogenic side-effects, it can inhibit both DNA synthesis and granulocyte-macrophage colony-forming cells (GM-CFC)growth and impaire the neogenesis of chromatin material and nuclear membrane during the M/G1 phase transition in K-562 cells. | |
| BCN1683 | Dehydro-alpha-lapachone |
| 1. Dehydro-alpha-lapachone is an antifungal substance. 2. Dehydro-α-lapachone can inhibit vessel regeneration, interfere with vessel anastomosis, and limit plexus formation in zebrafish, it also can induce vascular pruning and growth delay in orthotopic mammary tumors in mice. | |
| BCN1808 | Lavendustin A |
| 1. Lavendustin A and hormothamnione exhibit cytotoxic effects on tumor cell lines. 2. Lavendustin A is a potent tyrosine kinase inhibitor of the epidermal growth factor (EGF) receptor, and an angiogenesis inhibitor. 3. Lavendustin A is a hyperbolic mixed-type inhibitor with respect to both ATP and the peptide substrate, with a major effect on the binding affinities for both substrates. 4. Lavendustin A at 0.1 nM-1 microM causes a concave-shaped inhibition of the insulin release stimulated by 7 mM glucose, the inhibitory effect can be overcomed by higher concentrations of glucose. | |
| BCN1853 | Pramanicin |
| 1. Pramanicin, an antifungal agent, has vasorelaxant effect, it induces a slow endothelium-dependent relaxation, which could be reversed with the NO synthase inhibitor, L-NOARG . 2. Pramanicin has potent, selective, and irreversible inhibitory effect on the endothelial , thus it has potential development into an anti-angiogenic drug. 3. Pramanicin causes an initial slow endothelium-dependent, NO-mediated vascular relaxation, followed by a cytotoxic effect on vascular endothelial cells, eventually resulting in the loss of vasorelaxant function. 4. Pramanicin as a potential apoptosis-inducing small molecule, which acts through a well-defined JNK- and p38-dependent apoptosis signalling pathway in Jurkat T leukemia cells. 5. Pramanicin is an antimicrobial agent . | |
